Navigation Links
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Date:9/14/2009

2011.

VEGF Trap-Eye is also in Phase 2 development for the treatment of Diabetic Macular Edema (DME). VEGF Trap-Eye dosed at 0.5 mg or 2 mg monthly, 2 mg every eight weeks after three monthly loading doses, or 2 mg on an as-needed (PRN) basis after three monthly loading doses is being compared to focal laser treatment, the current standard of care in DME. The primary efficacy endpoint evaluation is mean improvement in visual acuity at six months. Patient enrollment has been completed with initial data expected in the first half of 2010.

About Wet AMD

Age-related Macular Degeneration (AMD) is a leading cause of acquired blindness. Macular degeneration is diagnosed as either dry (non-exudative) or wet (exudative). In wet AMD, new blood vessels grow beneath the retina and leak blood and fluid. This leakage causes disruption and dysfunction of the retina creating blind spots in central vision, and it can account for blindness in wet AMD patients. Wet AMD is the leading cause of blindness for people over the age of 65 in the U.S. and Europe.

About Regeneron

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST((R) )(rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's Web site at www.regeneron.com.

Forward Looking Statement - Regeneron Pharmaceuticals, Inc.

This news release discusses historical informa
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
2. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
5. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
8. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
9. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
10. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
11. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... and service provider for the medical industries, announced today the expansion ... New York City . genae Americas was incorporated ... is strategically centered in one of the highest concentrations of medical ... Philippe Kassab , President at genae Americas. "The expansion of genae ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... 2014 Beverly Hills licensed Clinical Psychologist ... celebrating 20 years of private practice in her Beverly ... to achieve greater joy and fulfillment in their relationships. ... signs and suggestions for anyone who suspects they are ... “Believe it or not, it’s not always easy to ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... Raleigh, NC (PRWEB) October 01, 2014 ... combination of three drugs that target immune system proteins ... Surviving Mesothelioma has just posted details of the new ... the story now. , Researchers in the UWA ... TGF-ß, and anti-CTLA-4 drugs to mice with mesothelioma with ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... to benefit a very special cause. The campaign—“Buy ... support for Paws for Veterans, a nonprofit organization ... while also rescuing shelter dogs that would otherwise ... of featured products will support monthly donations of ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... foundation set up by the Bill and Melinda Gates ... HIV-AIDS ambassador in India. // The officials said that ... the disease in the country.,The official release said that ... disease is a welcomed step in reducing the stigma ...
... is a country that wakes up to new things and accepts ... catching up.// Here doctors maintain there records in papers and are ... a job to document doctors’ patient records., ,In contrast, in ... maintained in the electronic format. ,MT industry in the US is ...
... benefit of doctors, hospitals and patients in mind a team ... will help doctors to prescribe prescriptions// to patients, based on ... Nicholson at Imperial College London led the study and made ... naturally by the body, in a group of rats before ...
... by the scientists at St. Jude Children’s Research Hospital ... suppressor gene resulted in aggressive leukemias.// Researchers have used ... and drug resistant nature of the acute lymphoblastic leukemia ... a mutation called Bcr-Abl and the loss of both ...
... of the money spent on buying over-the-counter cough medicines is ... so-called cough remedies may be ineffective. // It is stated ... year to these nonprescription cough medicines. ,There are many ... active ingredients in a limited number of strengths and combinations. ...
... accused China of removing organs from executed prisoners and ... their families//. ,There is increasing evidence, which ... for human transplantation purposes in an illegal way, according ... number of organs harvested from prisoners is currently unknown. ...
Cached Medicine News:Health News:Rising in career top charts is Medical transcription 2Health News:Mouse Models To Determine The Cause Of Aggressive Leukemia 2Health News:Mouse Models To Determine The Cause Of Aggressive Leukemia 3Health News:Executed Prisoner Organs For Sale In China: BTS Concerned 2
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... ISYSTEM-ABD ("I-cubed") is an exceptionally high ... analog oscilloscope (static deflection) display. This ... than low cost video monitors. Vitreous ... inflammatory cells, as well as tumor ...
... a sensitive B-scan system which quickly identifies ocular ... both eyes differ by more than 0.3 mm, ... suspected. The B5500 enables quick and easy identification ... bath or inserting shells under the lids. The ...
Medicine Products: